Block listing Interim Return

Shield Therapeutics PLC

03 October 2023

 

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

Block Listing 6 Monthly Return

Name of applicant:		SHIELD THERAPEUTICS PLC
Name of scheme:		Shield Therapeutics Retention Share Plan
Period of return:	From:	31 March 2023	To:	30 September 2023
Balance of unallotted securities under scheme(s) from previous return:		39,794
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		NIL
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		39,794

Name of applicant:		SHIELD THERAPEUTICS PLC
Name of scheme:		Shield Therapeutics plc 2016 Company Share Option Plan
Period of return:	From:	31 March 2023	To:	30 September 2023
Balance of unallotted securities under scheme(s) from previous return:		341,020
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		NIL
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		341,020

Name of applicant:		SHIELD THERAPEUTICS PLC
Name of scheme:		The Shield Therapeutics plc 2016 Long Term Incentive Plan
Period of return:	From:	31 March 2023	To:	30 September 2023
Balance of unallotted securities under scheme(s) from previous return:		24,273
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		NIL
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		24,273

Name of applicant:		SHIELD THERAPEUTICS PLC
Name of scheme:		Shield Therapeutics Retention and Performance Share Plan
Period of return:	From:	31 March 2023	To:	30 September 2023
Balance of unallotted securities under scheme(s) from previous return:		2,870,838
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		NIL
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		2,870,838

Name of contact:	Lucy Huntington-Bailey
Telephone number of contact:	[phone]

For further information please contact:

Shield Therapeutics plc	www.shieldtherapeutics.com
Greg Madison, CEO	[phone]
Hans-Peter Rudolf, CFO
Nominated Adviser and Joint Broker
Peel Hunt LLP
James Steel/Patrick Birkholm	[phone]
Joint Broker Cavendish Capital Markets Ltd      Geoff Nash/ George Dollemore/Nigel Birks/Harriet Ward	[phone]
Financial PR & IR Advisor
Walbrook PR
Lianne Applegarth/Alice Woodings	[phone] or [e-mail]
Investor Contact (US Advisor) LifeSci Advisors, LLC John Mullaly	[phone] or [e-mail]

About Accrufer®/Feraccru®

Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of action compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.

Accrufer®/Feraccru® has patent coverage until the mid-2030s

Accrufer®/Feraccru® are registered trademarks of the Shield Group

 

END